J. Baldridge

发表

Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells

M. Buchmeier, A. Paoletti, T. McGraw, 1997, Journal of virology.

Teratogenic effects of neonatal arenavirus infection on the developing rat cerebellum are abrogated by passive immunotherapy.

M. Buchmeier, B. Pearce, B. Parekh, 1993, Virology.

TTLR4 agonists as effective vaccine adjuvants

J. Baldridge, 2011 .

Antibody prevents the establishment of persistent arenavirus infection in synergy with endogenous T cells

M. Buchmeier, A. Paoletti, T. McGraw, 1997, Journal of virology.

Lymphocytic Choriomeningitis Virus Infection: Mother-to-Baby Transfer of Humoral Protectiont

M. Buchmeier, J. Baldridge, 2022 .

Toll-like receptor 4 agonists as vaccine adjuvants

D. Persing, C. Cuff, S. Mossman, 2006 .

Effective adjuvants for the induction of antigen-specific delayed-type hypersensitivity.

J. Ward, J. Baldridge, 1997, Vaccine.

Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration.

J. Ward, J. T. Ulrich, J. Baldridge, 2000, Vaccine.

Antigens and Adjuvants

S. Mossman, P. Algate, J. Baldridge, 2013 .

TLR4 agonists as immunomodulatory agents

M. Alderson, P. Mcgowan, P. Probst, 2006, Journal of endotoxin research.

Monophosphoryl Lipid A and Synthetic Lipid A Mimetics As TLR4-Based Adjuvants and Immunomodulators

D. Persing, R. Hershberg, C. Cluff, 2006 .

Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529

D. Persing, C. Cluff, J. Ward, 2002, Journal of endotoxin research.

Taking toll: lipid A mimetics as adjuvants and immunomodulators.

R. Coler, S. Reed, D. Persing, 2002, Trends in microbiology.

TLR4 Agonists as Vaccine Adjuvants

J. Baldridge, David A. Johnson, 2006 .

Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.

J. Baldridge, R. Crane, R.Thomas Crane, 1999, Methods.

Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529

D. Persing, C. Cluff, M. Lacy, 2003, Expert review of vaccines.

Expression of systemic protection and delayed-type hypersensitivity to Listeria monocytogenes is mediated by different T-cell subsets

D. Hinrichs, R. A. Barry, J. Baldridge, 1990, Infection and immunity.

Induction of immunity with avirulent Listeria monocytogenes 19113 depends on bacterial replication

M. Thomashow, D. Hinrichs, J. Baldridge, 1988, Infection and immunity.

TLR4 agonists as immunomodulatory agents.

M. Alderson, P. Mcgowan, P. Probst, 2006 .

Synthetic Toll-Like Receptor 4 Agonists Stimulate Innate Resistance to Infectious Challenge

D. Persing, R. Hershberg, C. Cluff, 2005, Infection and Immunity.

Structure-Activity Relationship of Synthetic Toll-like Receptor 4 Agonists*

D. Persing, R. Hershberg, R. Ulevitch, 2004, Journal of Biological Chemistry.

Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.

J. St-Jean, D. Larocque, J. Baldridge, 2016, Vaccine.

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

D. Persing, C. Cluff, S. Mossman, 2004, Expert opinion on biological therapy.

An H2-T MHC class Ib molecule presents Listeria monocytogenes-derived antigen to immune CD8+ cytotoxic T cells.

H. Bouwer, D. Hinrichs, R. A. Barry, 1994, Journal of immunology.

Mechanisms of antibody-mediated protection against lymphocytic choriomeningitis virus infection: mother-to-baby transfer of humoral protection

M. Buchmeier, J. Baldridge, 1992, Journal of virology.

A TLR4 agonist liposome formulation effectively stimulates innate immunity and enhances protection from bacterial infection

J. Hedges, M. Jutila, Amanda Robison, 2023, Innate immunity.